Allen Capital Group’s Nutex Health NUTX Stock Holding History

Allen Capital Group’s Portfolio NUTX Stock Details NUTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,983	Closed	-$371K	–	272
2025 Q2	$371K	Buy	+2,983	New	+$385K	0.04%	207

Other funds holding NUTX

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Allen Capital Group's NUTX Position: Q3 2025 in Review

Allen Capital Group sold out of Nutex Health (NUTX) in Q3 2025, closing a stake of 2,983 shares — an estimated $371K sold.

Allen Capital Group first reported a position in NUTX in Q2 2025 and held it in 1 quarter. The position peaked at $371K in Q2 2025. 95 funds tracked by Wall St. Rank hold NUTX as of Q3 2025.

Allen Capital Group reported no remaining Nutex Health position as of Q3 2025 after selling out during the quarter.
Allen Capital Group sold 2,983 Nutex Health shares in Q3 2025, an estimated $371K.
Allen Capital Group first reported a position in Nutex Health in Q2 2025 and held it in 1 quarter.
Allen Capital Group's Nutex Health position peaked at $371K in Q2 2025.
95 funds tracked by Wall St. Rank held Nutex Health as of Q3 2025.

Based on Allen Capital Group's 13F filing for Q3 2025, filed 27 Oct 2025.